Glaxo Partnership
EXTON, Pa. -(Dow Jones)- Adolor Corp. (ADLR) signed a development and commercialization agreement with GlaxoSmithKline PLC (GSK) for alvimopan, which manages bowel paralysis after surgery and constipation caused by opioid use.
In a press release Monday, Adolor said the companies also agreed to co - develop alvimopan, which is in Phase III development, for other acute and chronic indications that would involve the product's use in outpatient settings.
GlaxoSmithKline will pay Adolor a signing fee of $50 million and clinical and regulatory milestone payments of up to $220 million over the term of the agreement depending on the progress of the various indications.
In the U.S. , Adolor and GlaxoSmithKline will co -develop and co -promote alvimopan and share development expenses and commercial returns. Adolor will lead the development, marketing, and co -promotion strategy for acute-care indications, while GlaxoSmithKline will lead the development, marketing, and co -promotion for chronic-care indications targeted to community-based physicians.
Adolor discovers, develops and plans to commercialize pharmaceutical products.
Jack |
